World-leading University for research and education. Partnerships include business (e.g. GEHC, Roche,) the NHS (NIHR Oxford Biomedical Research Centre, Oxford University Hospitals Trust). For the rare cancer pilot, Oxford Sarcoma Service (Prof Hassan) and the Cancer Centre (e.g. Neuroendocrine) supra-regional hub and spoke care (10.5 million people). In education, courses respond leading-edge research, excellent facilities and high-quality transferable innovation skills.

EIT Health promotes entrepreneurship and innovates in healthy living and active ageing, providing Europe with new opportunities and resources. It enables citizens to lead healthier and more productive lives by delivering products, services and concepts that improve quality of life and contribute to the sustainability of healthcare across Europe.

State of art information technology (cloud, BI, big data, imaging) and solutions to enable collaboration between remote tumour boards and patients, analyse data for better understanding and predictability and therapeutic responses, create an expandable network, data and knowledge base for further utilization.

International network of 2,000 collaborators involved in cancer, in 300 university hospitals in 30 countries, 62 clinical trials in rare cancers over the past 15 years accruing a total of 20,123 patients. SPECTA is the project backbone and as platform for validating new heath technologies. Industry partners will access high-quality clinical material (clinical data, biological samples, linked imaging) necessary to validate new health technologies before market access.

In 2016 the European Commissions opened a call for interest in European Reference Networks.  The ultimate objective of such a network is to, “tackle complex and rare medical conditions that require highly specialised healthcare and a concentration of knowledge and resources”.

One of the world’s premier innovative biopharmaceutical companies. Pfizer is prioritizing its research and development efforts in oncology. Their specialized efforts in rare diseases and cancers illustrate their dedication to developing and delivering innovative treatments for the benefit of patients around the world.

Based in Hungary, Oncompass helps oncologists choose the most appropriate and effective treatment for their patients, based on the interpretation of molecular tests. Oncompass operates through a Swiss, a German and a Hungarian operating entity, receiving samples across Europe and providing state of the art, NGS based multi-gene and FISH testing. This system does not only empower doctors to make better decisions, but aims to build a coalition of all stakeholders to fight cancer (including oncologists, patients, diagnostic and pharma companies, as well as insurance companies, various other partners involved in enhancing decision making and therapy access).

LUMC is a modern university medical center for research, education and patient care with a high quality profile and a strong scientific orientation. Its unique research practice, ranging from pure fundamental medical research to applied clinical research, places LUMC among the world top. This enables LUMC to offer patient care and education that is in line with the latest international insights and standards – and helps it to improve medicine and healthcare both internally and externally.

One of the leading providers of clinical homecare and speciality pharmacy in Europe. With operating companies in the UK, Germany, Austria and Switzerland, Healthcare at Home serves more than 150,000 patients each year. Partnering with health systems and pharmaceutical companies, Healthcare at Home continues to develop innovative models of care that meet patients’ evolving needs outside of the hospital, in both conventional cancer treatment cases as well as in clinical trials, maintaining a high level of quality and safety.